A Safety and Efficacy Study of AGN-214868 in Patients With Postherpetic Neuralgia

Inclusion Criteria:

- Postherpetic neuralgia with pain present for at least 9 months

Exclusion Criteria:

- Active herpes zoster skin rash

- Anticipated treatment for postherpetic neuralgia during the first 3 months of the
study, including oral and topical medications, acupuncture, spinal cord stimulation,
transcutaneous nerve stimulation (TNS), or trigger point injection

- Anticipated treatment with pain medication for the treatment of postherpetic neuralgia
during the first 3 months of the study

- Use of capsaicin treatment for postherpetic neuralgia within 6 months, or anticipated
use during the first 3 months of the study

- Use of botulinum toxin of any serotype for any reason within 6 months, or anticipated
use during the study